



EURETINA 2025 Bayer Media Event: Dr. Amit Rakhit biography



Dr. Amit Rakhit

Chief Medical Officer, BlueRock Therapeutics

Dr. Amit Rakhit is an experienced pharmaceutical and biotech executive and has led teams developing medicines to transform medical practice across multiple therapeutic areas including oncology, neurology, rare diseases, and cardiovascular conditions.

His roles most recently have been in C-suite positions helping companies build and grow from the start-up phase through IPO to becoming operating entities. He is currently the Chief Medical Officer at BlueRock Therapeutics and focuses on stem cell therapies as potential treatment options for Parkinson's disease, inherited retinal diseases, and heart failure. Previously he was CEO at Flare Therapeutics and prior to this role, Amit was President and Chief Medical Officer at Ovid Therapeutics where he joined in the start-up phase and worked with the team through the IPO and subsequent pipeline development.

Between 2011-2016, Amit had senior-level roles at Biogen including Head of Worldwide Medical where he led a team of approximately 800 colleagues in medical activities for marketed and pipeline compounds in the disease areas of multiple sclerosis, neurodegenerative diseases, dementia, and hemophilia. Prior to this role he led the global programs in orphan and rare disorders for dexamipexole for ALS and Spinraza for spinal muscular atrophy.

Before Biogen he was with Bristol-Myers Squibb which brought him to Paris for 5 years leading first a European and then an international medical team across a global region spanning North and South America, Middle East, Africa, Australia and Pacific Rim with a cross-therapeutic area focus that included cardiovascular, metabolics, oncology, HIV, virology, immunology, and neuroscience products.

His education includes Harvard fellowship training in Pediatric Cardiology at Boston Children's Hospital, MD from Tufts University, a BA in molecular cell biology from the University of California, Berkeley, and MBA from the joint program between Columbia Business School and London Business School.